希少神経疾患治療の世界市場レポート 2025年

希少神経疾患治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.6％で148億4,000万米ドルに成長します。予測期間の成長は、診断ツールの改善、精密医療の進歩、患者中心の医薬品開発、実臨床エビデンスの統合、患者支援のための遠隔医療、個別化治療へのシフトなどに起因すると考えられます。予測期間における主な動向としては、技術革新、創薬におけるAI、データセキュリティのためのブロックチェーン、創薬における機械学習などが挙げられます。

希少神経疾患治療市場の予想成長は、希少な神経疾患の有病率によって牽引されると予想されます。これらの疾患は有病率が低いことが特徴で、ハンチントン病、筋萎縮性側索硬化症（ALS）、レット症候群、さまざまな形態の筋ジストロフィーなどの疾患が含まれます。希少な神経疾患の治療には、症状を管理し、病気の進行を遅らせ、罹患者の生活の質を高めるための多様なアプローチが用いられます。例えば、BioMed Central Ltd.が2023年1月に報告したように、レット症候群の集団有病率は、957万人の女性のサンプルサイズにおいて、女性10万人あたり7.1人であり、合計673人の症例が確認されました。したがって、希少な神経疾患の有病率は、希少神経疾患治療市場の成長を促進する重要な要因です。

ヘルスケア支出の増加は、今後の希少神経疾患治療市場の成長を促進すると予測されています。ヘルスケア支出には、健康を中心とした医療サービス、家族計画イニシアチブ、栄養プログラム、緊急支援などの提供に関連するすべてのコストが含まれます。ヘルスケア支出の増加は、研究、開発、専門的ケアへのアクセス、啓発を可能にし、これらはすべて希少神経疾患の治療改善や支援に不可欠です。例えば、2024年10月、チェコ共和国の政府機関であるチェコ統計局によると、総ヘルスケア支出は2021年の5,796億円から2022年には5,947億円に増加し、約2.6％の増加となった。その結果、ヘルスケア支出の増加が希少神経疾患治療市場の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界希少神経疾患治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の希少神経疾患治療市場：成長率分析
• 世界の希少神経疾患治療市場の実績：規模と成長, 2019-2024
• 世界の希少神経疾患治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界希少神経疾患治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の希少神経疾患治療市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生物学的製剤
• 小分子
• 世界の希少神経疾患治療市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 認知行動療法
• 対人関係心理療法
• サイバーナイフ
• その他の治療法
• 世界の希少神経疾患治療市場投与方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射可能
• その他の投与方法
• 世界の希少神経疾患治療市場疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アイカルディ症候群
• エカルディ・グティエール症候群
• 反射性交感神経性ジストロフィー症候群
• バタグリア・ネリ症候群
• クロイツフェルト・ヤコブ病
• 失認
• その他の疾患
• 世界の希少神経疾患治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局およびドラッグストア
• オンライン薬局
• 世界の希少神経疾患治療市場、生物製剤のサブセグメンテーション、薬剤タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 遺伝子治療
• 組み換えタンパク質
• 世界の希少神経疾患治療市場、小分子のサブセグメンテーション、薬物の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的小分子
• 神経保護剤
• 抗炎症小分子

第7章 地域別・国別分析

• 世界の希少神経疾患治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の希少神経疾患治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 希少神経疾患治療市場：競合情勢
• 希少神経疾患治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AbbVie Inc.
• Novartis AG
• Sanofi-Aventis SA
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Medtronic PLC
• Teva Pharmaceutical Industries Ltd.
• CSL Limited
• Biogen Inc.
• UCB S.A.
• Eisai Co. Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Jazz Pharmaceuticals PLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 希少神経疾患治療市場2029：新たな機会を提供する国
• 希少神経疾患治療市場2029：新たな機会を提供するセグメント
• 希少神経疾患治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Treatment for rare neurological diseases involves medical interventions and therapies with the goal of managing symptoms, slowing disease progression, and enhancing the quality of life for individuals affected by these uncommon conditions. Rare neurological diseases encompass disorders that affect the nervous system, including the brain, spinal cord, and peripheral nerves.

The primary types of treatment for rare neurological diseases involve drugs, including biologics and small molecules. Biologics, derived from living organisms such as proteins, antibodies, or nucleic acids, play a crucial role in treating rare neurological diseases. Examples include enzyme replacement therapies for lysosomal storage disorders and monoclonal antibodies for immune-mediated neurological disorders. Various therapies, such as cognitive behavioral therapy, interpersonal psychotherapy, and cyberknife, are administered through oral and injectable modes to address specific conditions such as Aicardi syndrome, Aicardi Goutieres syndrome, reflex sympathetic dystrophy syndrome, Battaglia-Neri syndrome, Creutzfeldt-Jakob disease, agnosia, and others. Medications are distributed through channels including hospitals, retail pharmacies, drug stores, and online pharmacies.

The rare neurological diseases treatment market research report is one of a series of new reports from The Business Research Company that provides rare neurological diseases treatment market statistics, including the rare neurological diseases treatment industry's global market size, regional shares, competitors with a rare neurological diseases treatment market share, detailed rare neurological diseases treatment market segments, rare neurological diseases treatment market trends and opportunities, and any further data you may need to thrive in the rare neurological diseases treatment industry. This rare neurological diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rare neurological disease treatment market size has grown strongly in recent years. It will grow from $9.85 billion in 2024 to $10.68 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to biosimilars in rare disease treatment, globalization of clinical trials, healthcare reimbursement policies, orphan drug designations, advancements in genetic research

The rare neurological disease treatment market size is expected to see strong growth in the next few years. It will grow to $14.84 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to improved diagnostic tools, precision medicine advancements, patient-centric drug development, integration of real-world evidence, telemedicine for patient support, shift towards personalized therapies. Major trends in the forecast period include technological innovations, ai in drug discovery, blockchain for data security, machine learning in drug discovery.

The anticipated growth of the rare neurological disease treatment market is expected to be driven by the prevalence of rare neurological diseases. These conditions, characterized by low prevalence, encompass disorders such as Huntington's disease, amyotrophic lateral sclerosis (ALS), Rett syndrome, and various forms of muscular dystrophy. Treating rare neurological diseases involves employing diverse approaches to manage symptoms, slow disease progression, and enhance the quality of life for affected individuals. For example, as reported in January 2023 by BioMed Central Ltd., the collective prevalence of Rett syndrome was determined to be 7.1 per 100,000 females in a sample size of 9.57 million women, with a total of 673 confirmed cases. Therefore, the prevalence of rare neurological diseases is a significant driver for the growth of the rare neurological disease treatment market.

The increase in healthcare expenditures is projected to drive the growth of the rare neurological disease treatment market in the future. Healthcare expenditures encompass all costs related to providing health services, family planning initiatives, nutrition programs, and emergency assistance, with a focus on health. Higher healthcare spending enables research, development, access to specialized care, and awareness, all of which are essential for improving treatments and support for rare neurological diseases. For example, in October 2024, the Czech Statistical Office, a governmental organization in the Czech Republic, reported that total healthcare expenditure rose from 579.6 billion in 2021 to 594.7 billion in 2022, representing an increase of about 2.6%. Consequently, the rise in healthcare expenditures is fueling the growth of the rare neurological disease treatment market.

A noteworthy trend gaining traction in the rare neurological disease treatment market is the development of orphan pharmaceuticals. Key companies in the sector are directing their efforts towards creating innovative and specialized treatments to solidify their market positions. For instance, in April 2023, French orphan drug development company Orphalan SA introduced Cuvrior, a novel trientine tetrahydrochloride (TETA-4HCl), in the European market. Cuvrior is commercially available for treating adult patients with stable Wilson disease who have undergone copper reduction therapy and exhibited tolerance to D-penicillamine. This drug received approval from the United States Food and Drug Administration (FDA) and was granted orphan drug exclusivity (ODE) in April 2022 for this specific patient population.

Major players in the rare neurological disease treatment market are placing a strong emphasis on product innovation, including rare disease drug development solutions, to advance therapeutic options and enhance the quality of life for patients affected by rare neurological diseases. Developing treatments for rare neurological diseases necessitates targeted research into specific disease mechanisms and the exploration of innovative therapeutic approaches, such as gene therapies or personalized medicine, to address the complex nature of these conditions. For instance, in February 2023, US-based pharmaceutical company Reata Pharmaceuticals Inc. received approval from the United States Food and Drug Administration (USFDA) for Skyclarys, a drug designed to treat Friedreich's ataxia, a rare neurological disease. Skyclarys represents an experimental medication addressing unmet needs in treating rare neurological conditions by targeting intricate disease mechanisms. It is undergoing rigorous clinical evaluation for its efficacy and safety profiles.

In February 2024, Harmony Biosciences, a biopharmaceutical company based in the United States, acquired Epygenix Therapeutics, Inc. for an undisclosed sum. The purpose of this acquisition is to improve treatments for rare epilepsy disorders such as Dravet syndrome and Lennox-Gastaut syndrome, thereby expediting the development of innovative therapies to address these unmet medical needs. Epygenix Therapeutics, Inc. is a clinical-stage biopharmaceutical company in the U.S. that focuses on developing and commercializing cutting-edge therapies.

Major companies operating in the rare neurological disease treatment market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi-Aventis SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Medtronic PLC, Teva Pharmaceutical Industries Ltd., CSL Limited, Biogen Inc., UCB S.A., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals PLC, Mitsubishi Tanabe Pharma Corporation, Neurocrine Biosciences Inc., Kedrion Biopharma Inc., Merz Pharma GmbH & Co. KGaA, Harmony Biosciences Holdings Inc., Amicus Therapeutics Inc., Revance Therapeutics Inc., Aquestive Therapeutics Inc., US WorldMeds LLC (Solstice Neurosciences LLC), Stoke Therapeutics Inc., Retrotope Inc.

North America was the largest region in the rare neurological disease's treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare neurological disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the rare neurological disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare neurological disease treatment market consists of revenues earned by entities by providing supportive care services and neurodegenerative research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare neurological disease treatment market also includes sales of anticonvulsants, antidepressants, and beta blockers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Neurological Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare neurological disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rare neurological disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rare neurological disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Biologics; Small Molecules
• 2) By Therapy: Cognitive Behavioral Therapy; Interpersonal Psychotherapy; Cyberknife; Other Therapies
• 3) By Mode Of Administration: Oral; Injectable; Other Modes Of Administration
• 4) By Disorders: Aicardi Syndrome; Aicardi-Goutieres Syndrome; Reflex Sympathetic Dystrophy Syndrome; Battaglia-Neri Syndrome; Creutzfeldt Jakob Disease; Agnosia; Other Disorders
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies And Drug Store; Online Pharmacies
• Subsegments:
• 1) By Biologics: Monoclonal Antibodies; Gene Therapies; Recombinant Proteins
• 2) By Small Molecules: Targeted Small Molecules; Neuroprotective Agents; Anti-inflammatory Small Molecules
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd; Bayer AG; Merck & Co. Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rare Neurological Disease Treatment Market Characteristics

3. Rare Neurological Disease Treatment Market Trends And Strategies

4. Rare Neurological Disease Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Rare Neurological Disease Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Rare Neurological Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Rare Neurological Disease Treatment Market Growth Rate Analysis
• 5.4. Global Rare Neurological Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Rare Neurological Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Rare Neurological Disease Treatment Total Addressable Market (TAM)

6. Rare Neurological Disease Treatment Market Segmentation

• 6.1. Global Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics
• Small Molecules
• 6.2. Global Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cognitive Behavioral Therapy
• Interpersonal Psychotherapy
• Cyberknife
• Other Therapies
• 6.3. Global Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Modes Of Administration
• 6.4. Global Rare Neurological Disease Treatment Market, Segmentation By Disorders, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aicardi Syndrome
• Aicardi-Goutieres Syndrome
• Reflex Sympathetic Dystrophy Syndrome
• Battaglia-Neri Syndrome
• Creutzfeldt Jakob Disease
• Agnosia
• Other Disorders
• 6.5. Global Rare Neurological Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies And Drug Store
• Online Pharmacies
• 6.6. Global Rare Neurological Disease Treatment Market, Sub-Segmentation Of Biologics, By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Gene Therapies
• Recombinant Proteins
• 6.7. Global Rare Neurological Disease Treatment Market, Sub-Segmentation Of Small Molecules, By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Small Molecules
• Neuroprotective Agents
• Anti-inflammatory Small Molecules

7. Rare Neurological Disease Treatment Market Regional And Country Analysis

• 7.1. Global Rare Neurological Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Rare Neurological Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rare Neurological Disease Treatment Market

• 8.1. Asia-Pacific Rare Neurological Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rare Neurological Disease Treatment Market

• 9.1. China Rare Neurological Disease Treatment Market Overview
• 9.2. China Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rare Neurological Disease Treatment Market

• 10.1. India Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rare Neurological Disease Treatment Market

• 11.1. Japan Rare Neurological Disease Treatment Market Overview
• 11.2. Japan Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rare Neurological Disease Treatment Market

• 12.1. Australia Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rare Neurological Disease Treatment Market

• 13.1. Indonesia Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rare Neurological Disease Treatment Market

• 14.1. South Korea Rare Neurological Disease Treatment Market Overview
• 14.2. South Korea Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rare Neurological Disease Treatment Market

• 15.1. Western Europe Rare Neurological Disease Treatment Market Overview
• 15.2. Western Europe Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rare Neurological Disease Treatment Market

• 16.1. UK Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rare Neurological Disease Treatment Market

• 17.1. Germany Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rare Neurological Disease Treatment Market

• 18.1. France Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rare Neurological Disease Treatment Market

• 19.1. Italy Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rare Neurological Disease Treatment Market

• 20.1. Spain Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rare Neurological Disease Treatment Market

• 21.1. Eastern Europe Rare Neurological Disease Treatment Market Overview
• 21.2. Eastern Europe Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rare Neurological Disease Treatment Market

• 22.1. Russia Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rare Neurological Disease Treatment Market

• 23.1. North America Rare Neurological Disease Treatment Market Overview
• 23.2. North America Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rare Neurological Disease Treatment Market

• 24.1. USA Rare Neurological Disease Treatment Market Overview
• 24.2. USA Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rare Neurological Disease Treatment Market

• 25.1. Canada Rare Neurological Disease Treatment Market Overview
• 25.2. Canada Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rare Neurological Disease Treatment Market

• 26.1. South America Rare Neurological Disease Treatment Market Overview
• 26.2. South America Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rare Neurological Disease Treatment Market

• 27.1. Brazil Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rare Neurological Disease Treatment Market

• 28.1. Middle East Rare Neurological Disease Treatment Market Overview
• 28.2. Middle East Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rare Neurological Disease Treatment Market

• 29.1. Africa Rare Neurological Disease Treatment Market Overview
• 29.2. Africa Rare Neurological Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Rare Neurological Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Rare Neurological Disease Treatment Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rare Neurological Disease Treatment Market Competitive Landscape And Company Profiles

• 30.1. Rare Neurological Disease Treatment Market Competitive Landscape
• 30.2. Rare Neurological Disease Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Rare Neurological Disease Treatment Market Other Major And Innovative Companies

• 31.1. AbbVie Inc.
• 31.2. Novartis AG
• 31.3. Sanofi-Aventis SA
• 31.4. Bristol-Myers Squibb Company
• 31.5. AstraZeneca PLC
• 31.6. GlaxoSmithKline PLC
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Medtronic PLC
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. CSL Limited
• 31.11. Biogen Inc.
• 31.12. UCB S.A.
• 31.13. Eisai Co. Ltd.
• 31.14. Otsuka Pharmaceutical Co. Ltd.
• 31.15. Jazz Pharmaceuticals PLC

32. Global Rare Neurological Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rare Neurological Disease Treatment Market

34. Recent Developments In The Rare Neurological Disease Treatment Market

35. Rare Neurological Disease Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Rare Neurological Disease Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Rare Neurological Disease Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Rare Neurological Disease Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer